| Sign In to gain access to subscriptions and/or personal tools. |
Antinociceptive effect of spinally administered cannabinergic and
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract |
|---|
The current experiments were designed to study the antinociceptive effects of
intrathecal (i.t.) administration of cannabinoid CB1 receptor and
2-adrenoceptor drugs in the nociceptive processing and also
their receptor interactions. Different doses of a cannabinoid receptor agonist, CP
55,940, and an
2-adrenoceptor agonist, clonidine induced a
dose-dependent antinociception in both phases of the formalin test.
CP 55,940-induced antinociception was reduced by pretreatment of a selective
cannabinoid CB1 receptor antagonist, SR 141716A, but not by pretreatment
with an
2-adrenoceptor antagonist, yohimbine in both phases of
the test. However, yohimbine and SR 141716A attenuated the antinociception induced
by clonidine in the early phase but not in the late phase of the test. While SR
141716A by itself did not influence pain behaviour, the reversal effect of clonidine
by SR 141716A indicate that clonidine stimulate the release of endocannabinoid(s).
In conclusion, our findings may suggest that: (1) spinal cannabinoid and
2-adrenoceptor systems are able to induce antinociception in
both phases of formalin test, and (2) the cannabinoid system may be involved in the
antinociception induced by adrenoceptors in the early phase.
Key Words:
cannabinoid receptor,
2-adrenoceptor, antinociception, intrathecal, drug interactions
First published on September 20, 2005, doi:10.1177/0269881105056996
Journal of Psychopharmacology 2006;20:67.
A more recent version of this article appeared on January 1, 2006
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
2-adrenoceptor drugs on the formalin test in rat: possible interactions